Book a Meeting

Non-Fucosylated Anti-Human Integrin α8β1 (#5) Therapeutic Antibody (CAT#: BioBet-1118ZP) Datasheet

Target
Integrin α8β1
Isotype
IgY
Description
ADCC-Enhanced anti-Integrin α8β1 (#5) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Indication
Cancer; Arthritis,
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Integrin α8β1 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
Integrin α8β1
Full Name
Integrin α8β1
Background
The integrin α8β1, in general, is a heterodimer consisting of α and β chains and is a receptor protein present on the cell surface. Its DNA and amino acid sequences have been deposited and can be referred to.
Alternative Names
Integrin α8β1
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with ITGA8 include Renal Hypodysplasia/Aplasia 1 and Renal Agenesis, Bilateral.
Related Pathways
Its related pathways are Integrin Pathway and Degradation of the extracellular matrix.
Function
Integrin alpha-8/beta-1 plays a role in the development of kidney and other organs by regulating the recruitment of mesenchymal cells to epithelial structures. It can recognize the R-G-D sequence in various ligands such as TNC, FN1, SPP1, TGFB1, TGFB3 and VTN. NPNT may be its functional ligand in renal development. The neuronal receptor of TNC, which mediates the interaction between cells and regulates the growth of sensory and motor neurons.
Post-translational modifications
1.Glycosylation at Asn81, Asn122, Asn177, Asn239, Asn302, Asn311, Asn504, Asn601, Asn605, Asn719, Asn737, Asn753, Asn780, Asn896, Asn923, and Asn1005 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgY
Antibody Clone
#5
Host
Chicken
Species Reactivity
Human
Description
The anti-integrin α8β1 antibody which bind to integrin α8β1 derived from mammals of different species are used for diagnosis of cancer, arthritis, glaucoma, or neuropathic pain.
Indication
Cancer; Arthritis,

Cancer; Arthritis,

Related Products

Non-Fucosylated Anti-Human Integrin α8β1 (#26) Therapeutic Antibody (CAT#: BioBet-1119ZP)
Non-Fucosylated Anti-Human Integrin α8β1 (#3) Therapeutic Antibody (CAT#: BioBet-1117ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.